Price (delayed)
$0.5
Market cap
$55.92M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.81
Enterprise value
$148.68M
Founded in 2003, Athenex, Inc. is a global clinical stage biopharmaceutical company dedicated to becoming a leader in the discovery, development, and commercialization of next generation drugs for the treatment
There are no recent dividends present for ATNX.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.